Shuren On US vs EU: FDA Strikes The Right Regulatory Balance
This article was originally published in SRA
Executive Summary
While the medtech industry has often complained about how much longer it takes to get devices into the US compared with Europe, Jeff Shuren, director of the US FDA's device center thinks the agency has struck the right regulatory balance between public safety and an environment to allow innovation.
You may also be interested in...
Initial Survey Results Show Overwhelming Satisfaction With FDA Device Center Customer Service
While there are still a few months to go before the US FDA's Center for Devices and Radiological Health closes its customer service survey, the initial results look to be trending in the agency's favor. With almost nine-in-ten respondents giving a positive review, the results support the agency's efforts to improve customer service.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.